World Ovarian Cancer Day to be observed May 8
Thursday is World Ovarian Cancer Day, an annual effort to raise awareness about ovarian cancer, the second most common type of gynecological cancer.
News
Linvoseltamab, now Lynozyfic, earns EU’s conditional OK to treat RRMM
The European Commission (EC) has conditionally approved Regeneron Pharmaceuticals’ linvoseltamab, now Lynozyfic, to treat adults with relapsed or refractory multiple myeloma (RRMM).
EU committee recommends fixed-duration Calquence combo for CLL
A European regulatory committee has recommended approval of a fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) for adults with previously untreated chronic lymphocytic leukemia…
FDA OKs clinical testing of oral treatment for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has given Verastem Oncology the green light to start clinical testing of its oral treatment candidate VS-7375…
Supporters to #GoGrayinMay for Brain Tumor Awareness Month
Each May marks Brain Tumor Awareness Month, with annual efforts to raise awareness about glioma and other types of cancer that affect the brain.
Tepylute for breast, ovarian cancer launched in US
Tepylute (thiotepa), a chemotherapy medication from Shorla Oncology that was approved last year for treating certain breast and ovarian cancers, has launched in the…
Trial data for 2 Caribou CAR T-cell therapies due this year
Caribou Biosciences is reprioritizing its pipeline to focus on two of its CAR T-cell therapies for blood cancer, including one, CB-011, that’s being developed…
Blocking LSD1, GSK3 could be treatment strategy for AML
Simultaneously blocking the activity of two proteins, LSD1 and GSK3, may be an effective strategy to treat acute myeloid leukemia (AML), an aggressive type of…
MUC5AC protein could predict pancreatic cancer prognosis: Study
Blood levels of the MUC5AC protein could help predict outcomes in people who have surgery for pancreatic ductal adenocarcinoma (PDA), the most common type of…
BCB-276 for DIPG brain cancer named FDA breakthrough therapy
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to the cell therapy BCB-276 as a potential treatment for diffuse intrinsic…
